These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 23965899)
1. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899 [TBL] [Abstract][Full Text] [Related]
2. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Dai W; Teodoridis JM; Zeller C; Graham J; Hersey J; Flanagan JM; Stronach E; Millan DW; Siddiqui N; Paul J; Brown R Clin Cancer Res; 2011 Jun; 17(12):4052-62. PubMed ID: 21459799 [TBL] [Abstract][Full Text] [Related]
3. Acquired Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239 [TBL] [Abstract][Full Text] [Related]
4. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma. Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581 [TBL] [Abstract][Full Text] [Related]
5. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer. Choi J; Topouza DG; Tarnouskaya A; Nesdoly S; Koti M; Duan QL BMC Cancer; 2020 May; 20(1):413. PubMed ID: 32404140 [TBL] [Abstract][Full Text] [Related]
6. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy. Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501 [TBL] [Abstract][Full Text] [Related]
7. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer. Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408 [TBL] [Abstract][Full Text] [Related]
8. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578 [TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium. Guan J; Darb-Esfahani S; Richter R; Taube ET; Ruscito I; Mahner S; Woelber L; Prieske K; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI J Cancer Res Clin Oncol; 2019 Apr; 145(4):1063-1073. PubMed ID: 30810838 [TBL] [Abstract][Full Text] [Related]
10. Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma. Romeo M; Karachaliou N; Chaid I; Queralt C; De Aguirre I; Del Carmen Gómez M; Sanchez-Ronco M; Radua J; Ramírez JL; Rosell R Int J Biol Markers; 2017 Mar; 32(1):e90-e95. PubMed ID: 27443420 [TBL] [Abstract][Full Text] [Related]
11. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392 [TBL] [Abstract][Full Text] [Related]
12. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype. Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568 [TBL] [Abstract][Full Text] [Related]
13. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442 [TBL] [Abstract][Full Text] [Related]
14. Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer. Zhang G; Zhang J; Zhu Y; Liu H; Shi Y; Mi K; Li M; Zhao Q; Huang Z; Huang J Exp Cell Res; 2021 Sep; 406(1):112742. PubMed ID: 34302857 [TBL] [Abstract][Full Text] [Related]
15. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. Keita M; Wang ZQ; Pelletier JF; Bachvarova M; Plante M; Gregoire J; Renaud MC; Mes-Masson AM; Paquet ÉR; Bachvarov D Gynecol Oncol; 2013 Feb; 128(2):356-63. PubMed ID: 23219462 [TBL] [Abstract][Full Text] [Related]
16. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer. Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer. Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252 [TBL] [Abstract][Full Text] [Related]
18. Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Garès V; Christie EL; Wouters MCA; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart CJR; Sharma R; Allan PE; Rambau PF; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Köbel M; Harnett P; Nelson BH; Bowtell DDL; deFazio A; Clin Cancer Res; 2018 Feb; 24(3):569-580. PubMed ID: 29061645 [No Abstract] [Full Text] [Related]
19. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. Xu X; Deng F; Lv M; Ren B; Guo W; Chen X J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779 [TBL] [Abstract][Full Text] [Related]
20. Methylomic Signatures of High Grade Serous Ovarian Cancer. Cardenas H; Fang F; Jiang G; Perkins SM; Zhang C; Emerson RE; Hutchins G; Keer HN; Liu Y; Matei D; Nephew K Epigenetics; 2021 Nov; 16(11):1201-1216. PubMed ID: 33289590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]